Date of preparation April 2014 │BRI001081 ACC.14 Annual Scientific Sessions of the American College of Cardiology Washington DC 29-31 March 2014
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Date of preparation April 2014 │BRI001081
ACC.14Annual Scientific Sessions of the American College of Cardiology
Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
Disclaimer
• AstraZeneca abides by the Medicines Australia Code of Conduct (Edition 17) and AstraZeneca Global Policies, and as such will not engage in the promotion of unregistered products or unapproved indications.
• These highlights have been suggested by a group of cardiologists who attended ACC.14, compiled by an external medical writer and sponsored by AstraZeneca.
• Statements of fact and opinions expressed are those of the speakers individually and, unless expressly stated to the contrary, are not the opinion or position of AstraZeneca. AstraZeneca does not endorse or approve, and assumes no responsibility for, the content, accuracy, or completeness of the information presented. Presentations are intended for educational purposes only and do not replace independent professional judgement.
• Please refer to the appropriate approved Product Information before prescribing any agents mentioned in these highlights.
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
MADIT-CRT: Long-term follow-up in mild heart failure patients
Commentary:
Associate Professor Chris ZeitzQueen Elizabeth Hospital, Adelaide
Late-breaking trial
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Initial study: 2.4 year follow-up
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
No benefit, possible harm in absence of LBBB
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
• Long-term follow-up of the MADIT CRT cohort supports our current practice of implementing early CRT in patients with mild heart failure and LBBB.
• The number needed to treat with CRT is similar to that for medical therapy.
Commentary: Associate Professor Chris Zeitz
Related Documents
![[XLS]servicioscompartidos.uniandes.edu.co · Web view2 4 6 9 6 9 6 9 6 9 6 9 9 9 9 9 9 7 9 9 9 9 9 7 9 7 9 7 9 4 6 9 9 9 9 9 4 6 9 4 6 9 4 6 9 4 6 9 6 9 4 6 9 9 9 9 9 4 6 9 9 9 9](https://static.cupdf.com/doc/110x72/5be14b3a09d3f232098d2967/xls-web-view2-4-6-9-6-9-6-9-6-9-6-9-9-9-9-9-9-7-9-9-9-9-9-7-9-7-9-7-9-4-6.jpg)
